Why older hereditary cancer tests may need a second look

A recent Washington Post report highlighted this shift and the growing advice that some people with older, limited hereditary cancer tests should ask whether repeat testing is now appropriate. Medical references and genetics guidance support the basic idea: a negative result from limited testing does not necessarily rule out an inherited cancer risk if the test only examined part of the relevant genetics. https://www.washingtonpost.com/health/2026/10/12/women-once-cleared-by-genetic-tests-cancer-risks-now-consider-retesting/

What changed in hereditary cancer testing

Early hereditary cancer testing often focused on a small number of BRCA1 and BRCA2 changes, or used methods that were not as good at finding larger rearrangements and additional cancer-related genes. Today, many clinical tests use multigene panels that can look across several genes linked to inherited cancer risk, not just BRCA1 and BRCA2. That broader approach can pick up pathogenic variants that older testing would have missed. https://pmc.ncbi.nlm.nih.gov/articles/PMC6733830/

MedlinePlus notes that BRCA testing is used when a person or clinician is concerned about a harmful variant and that positive results can lead to discussions about ways to lower cancer risk, including enhanced screening or risk-reducing surgery in some cases. The key point is that test results can affect prevention choices, so the scope of the test matters. https://medlineplus.gov/lab-tests/brca-test/

Why the story matters

For people with a strong personal or family history of cancer, a negative result from older limited testing may have offered false reassurance. The National Cancer Institute’s cancer genetics guidance says that for high-risk individuals, a negative result from limited testing is incomplete because it may not assess other pathogenic variants in BRCA1 or BRCA2 or in many other cancer-associated genes. https://www.ncbi.nlm.nih.gov/books/NBK65817.30/

That does not mean everyone with an older test needs to rush back for more testing. But it does mean the result should be interpreted in the context of what the test actually covered. If the original test only looked for a subset of BRCA changes, or if it was done before multigene panels became common, the answer may no longer be sufficiently comprehensive for current decision-making. https://pmc.ncbi.nlm.nih.gov/articles/PMC6733830/

What the evidence actually shows

The evidence behind retesting comes from the evolution of genetic technology and from studies showing that broader panels find additional actionable variants. The American Society of Breast Surgeons’ consensus guidance explains that next-generation sequencing made panel testing more practical and that broader testing can increase the detection of pathogenic variants beyond BRCA1 and BRCA2. https://pmc.ncbi.nlm.nih.gov/articles/PMC6733830/

Research summarized in the NCBI materials also shows that commercially available multigene panels have identified substantial numbers of pathogenic variants across genes such as ATM, CHEK2, and PALB2, not just BRCA1 and BRCA2. In other words, a person can test negative on an older BRCA-focused assay and still carry a clinically important inherited risk variant elsewhere. https://www.ncbi.nlm.nih.gov/sites/books/NBK545867/pdf/Bookshelf_NBK545867.pdf

Some studies and reviews go further and suggest retesting when prior testing was limited and clinical suspicion remains high. That is a reasonable inference from the literature, but it is not the same as proving that every person with an older negative result will benefit from reanalysis. The practical value depends on the original test, the family history, and whether a newer result would change care. https://pmc.ncbi.nlm.nih.gov/articles/PMC5410210/

What remains uncertain

Not every newly detected variant leads to a clear action. Some findings are still uncertain, and genetics experts may not be able to say exactly how much a particular variant changes cancer risk. The Washington Post article noted that broader testing can also produce uncertainty, which is one reason retesting should be discussed with a clinician or genetic counselor rather than treated as a simple yes-or-no upgrade. https://www.washingtonpost.com/health/2026/10/12/women-once-cleared-by-genetic-tests-cancer-risks-now-consider-retesting/

There is also a difference between finding a variant and knowing what to do with it. Some results support changes in screening or prevention, while others may not immediately change management. That is why test interpretation matters as much as the lab report itself. https://medlineplus.gov/lab-tests/brca-test/

What to discuss with a clinician

People who had hereditary cancer testing years ago may want to review three questions: what genes were tested, what kinds of changes the test could detect, and whether there is any new family or personal cancer history that changes the picture. If the original test was limited, or if it predated current multigene panels, retesting could be worth discussing. https://www.ncbi.nlm.nih.gov/books/NBK65817.30/

It can also help to bring copies of old lab reports, because the exact assay matters. A result that was considered thorough in the early days of BRCA testing may not match current standards for hereditary cancer evaluation. https://pmc.ncbi.nlm.nih.gov/articles/PMC5006185/

This is not a recommendation for people to change screening or treatment on their own. But it is a reminder that genetic information is not static. As testing methods improve, an older negative result may deserve a second look, especially when it was based on a narrower panel than what is available now. If you have symptoms concerning for cancer, or a strong family history that has not been fully evaluated, timely medical follow-up is important. https://www.washingtonpost.com/health/2026/10/12/women-once-cleared-by-genetic-tests-cancer-risks-now-consider-retesting/